Theralink(R) Technologies to Present at the LD 500 Virtual Conference on September 1st

Rhea-AI Summary

OncBioMune d/b/a Theralink Technologies (OTC PINK:OBMP) announced that its CEO, Mick Ruxin, M.D., will present at the LD 500 Virtual Conference on September 1, 2020, at 10:40 a.m. ET. The conference, running from September 1-4, 2020, will feature public companies and influential business leaders discussing the small-cap sector. Theralink is known for its patented biomarker assay services in oncology, aiming to improve cancer treatment outcomes through precision data. For participation, registration is required via a provided link.

DENVER, CO / ACCESSWIRE / August 25, 2020 / OncBioMune d/b/a Theralink Technologies (OTC PINK:OBMP) ("Theralink" or the "Company"), a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, announced today that Mick Ruxin, M.D., President and CEO of Theralink, will present at the LD 500 Virtual Conference on Tuesday, September 1, 2020.

Dr. Ruxin will present via live webcast at 10:40 a.m. ET in Track 3. To attend, please register here: https://www.webcaster4.com/Webcast/Page/2019/36068

The LD 500 Virtual Conference taking place from September 1-4, 2020 will feature prominent public companies, alongside interviews and keynotes with some of the most successful and influential business leaders in the small-cap world.

For more information about the LD 500, or to schedule a one-on-one meeting with Theralink's management, please contact Theralink's Investor Relations at Theralink@kcsa.com or David Scher at david@ldmicro.com.

About Theralink® Technologies, Inc.

Theralink Technologies is a proteomics-based, molecular profiling company, located in Golden, Colorado that uniquely specializes in patented, phosphoprotein and protein biomarker assay services that target multiple areas of oncology. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. We intend to improve cancer outcomes for patients, reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.

Contact Information

Theralink Technologies, Inc.
KCSA Strategic Communications
Valter Pinto, Managing Director
212.896.1254
valter@kcsa.com

SOURCE: Theralink Technologies

View source version on accesswire.com:
https://www.accesswire.com/603190/TheralinkR-Technologies-to-Present-at-the-LD-500-Virtual-Conference-on-September-1st

FAQ

When will OncBioMune present at the LD 500 Virtual Conference?

OncBioMune will present on September 1, 2020, at 10:40 a.m. ET.

What is the significance of the LD 500 Virtual Conference?

The LD 500 Virtual Conference features public companies and influential leaders in the small-cap sector, occurring from September 1-4, 2020.

How can I register for the LD 500 Virtual Conference?

You can register for the conference through the web link provided in the press release.

What services does Theralink Technologies offer?

Theralink specializes in patented biomarker assay services for oncology, focusing on precision data to improve cancer treatment.

What is the stock symbol for OncBioMune?

The stock symbol for OncBioMune is OBMP.